Neuroscience, Ophthalmology and Rare Diseases


With a strong and diverse portfolio covering the most common to the rarest neurological conditions, Roche is approaching neuroscience and rare diseases with curiosity, passion and rigor to follow the science to improve the lives of people.

In ophthalmology we combine our in-depth understanding of the underlying disease biology, with new data and analytical sources such as real-world data, machine learning, and advanced algorithms. This approach will potentially allow us to design and assess therapies that target new pathways, work in novel ways or are administered via long-acting delivery mechanisms.

Partnering opportunities we are looking for:

  • Neurodegeneration (e.g. Alzheimer's disease, Parkinson's disease, Huntington disease, Amyotrophic lateral sclerosis)
  • Neuroinflammation (e.g. Multiple sclerosis)
  • Neurodevelopmental (e.g. Autistic spectrum disorder)
  • Pain (non-opioid treatments for chronic pain)
  • Retinal diseases and dry eye disease
  • Monogenetic rare diseases

Example partnerships

Convelo Therapeutics – collaboration to discover and develop novel remyelinating medicines for patients with neurological disorders

Kineta Inc. – collaboration to explore novel non-opioid treatments for chronic pain

PTC and SMA foundation – collaboration to explore oral therapies for SMA

Forsight Vision4 – Acquisition to acquire Port Delivery system for long-acting ocular delivery

Your dedicated partnering leads for Neuroscience, Ophthalmology and Rare Diseases

Thomas F. Zioncheck

Thomas F. Zioncheck Head of Neuroscience, Ophthalmology & Rare Diseases, Pharma Partnering

J.C. Lopez

J.C. Lopez Search & Evaluation Lead Neuroscience, Ophthalmology & Rare Diseases, Pharma Partnering partnering

If you have an opportunity, we would like to hear from you.

Contact us

Related links